12-21560399-G-A
Position:
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_021957.4(GYS2):c.1156C>T(p.Arg386*) variant causes a stop gained change. The variant allele was found at a frequency of 0.0000598 in 1,588,950 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★). Variant results in nonsense mediated mRNA decay.
Frequency
Genomes: 𝑓 0.000046 ( 0 hom., cov: 33)
Exomes 𝑓: 0.000061 ( 0 hom. )
Consequence
GYS2
NM_021957.4 stop_gained
NM_021957.4 stop_gained
Scores
4
2
1
Clinical Significance
Conservation
PhyloP100: 4.77
Genes affected
GYS2 (HGNC:4707): (glycogen synthase 2) The protein encoded by this gene, liver glycogen synthase, catalyzes the rate-limiting step in the synthesis of glycogen - the transfer of a glucose molecule from UDP-glucose to a terminal branch of the glycogen molecule. Mutations in this gene cause glycogen storage disease type 0 (GSD-0) - a rare type of early childhood fasting hypoglycemia with decreased liver glycogen content. [provided by RefSeq, Dec 2009]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 18 ACMG points.
PVS1
Loss of function variant, product undergoes nonsense mediated mRNA decay. LoF is a known mechanism of disease.
PM2
Very rare variant in population databases, with high coverage;
PP5
Variant 12-21560399-G-A is Pathogenic according to our data. Variant chr12-21560399-G-A is described in ClinVar as [Pathogenic]. Clinvar id is 569452.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
GYS2 | NM_021957.4 | c.1156C>T | p.Arg386* | stop_gained | 8/16 | ENST00000261195.3 | NP_068776.2 | |
GYS2 | XM_024448960.2 | c.1156C>T | p.Arg386* | stop_gained | 8/17 | XP_024304728.1 | ||
GYS2 | XM_006719063.4 | c.925C>T | p.Arg309* | stop_gained | 7/15 | XP_006719126.1 | ||
GYS2 | XM_017019245.3 | c.1156C>T | p.Arg386* | stop_gained | 8/9 | XP_016874734.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
GYS2 | ENST00000261195.3 | c.1156C>T | p.Arg386* | stop_gained | 8/16 | 1 | NM_021957.4 | ENSP00000261195.2 | ||
ENSG00000285854 | ENST00000647960.1 | n.*1158C>T | non_coding_transcript_exon_variant | 15/23 | ENSP00000497202.1 | |||||
ENSG00000285854 | ENST00000647960.1 | n.*1158C>T | 3_prime_UTR_variant | 15/23 | ENSP00000497202.1 | |||||
ENSG00000285854 | ENST00000648372.1 | n.1083C>T | non_coding_transcript_exon_variant | 8/11 |
Frequencies
GnomAD3 genomes AF: 0.0000460 AC: 7AN: 152138Hom.: 0 Cov.: 33
GnomAD3 genomes
AF:
AC:
7
AN:
152138
Hom.:
Cov.:
33
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.0000477 AC: 12AN: 251334Hom.: 0 AF XY: 0.0000810 AC XY: 11AN XY: 135840
GnomAD3 exomes
AF:
AC:
12
AN:
251334
Hom.:
AF XY:
AC XY:
11
AN XY:
135840
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.0000612 AC: 88AN: 1436812Hom.: 0 Cov.: 31 AF XY: 0.0000712 AC XY: 51AN XY: 716498
GnomAD4 exome
AF:
AC:
88
AN:
1436812
Hom.:
Cov.:
31
AF XY:
AC XY:
51
AN XY:
716498
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0000460 AC: 7AN: 152138Hom.: 0 Cov.: 33 AF XY: 0.0000538 AC XY: 4AN XY: 74316
GnomAD4 genome
AF:
AC:
7
AN:
152138
Hom.:
Cov.:
33
AF XY:
AC XY:
4
AN XY:
74316
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
TwinsUK
AF:
AC:
0
ALSPAC
AF:
AC:
1
ExAC
AF:
AC:
6
EpiCase
AF:
EpiControl
AF:
ClinVar
Significance: Pathogenic
Submissions summary: Pathogenic:2
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
Glycogen storage disorder due to hepatic glycogen synthase deficiency Pathogenic:2
Pathogenic, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Oct 31, 2018 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Dec 21, 2020 | This sequence change creates a premature translational stop signal (p.Arg386*) in the GYS2 gene. It is expected to result in an absent or disrupted protein product. For these reasons, this variant has been classified as Pathogenic. Loss-of-function variants in GYS2 are known to be pathogenic (PMID: 9691087). This variant has not been reported in the literature in individuals with GYS2-related disease. This variant is present in population databases (rs146195866, ExAC 0.02%). - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_addAF
Pathogenic
D
BayesDel_noAF
Pathogenic
CADD
Pathogenic
DANN
Uncertain
Eigen
Pathogenic
Eigen_PC
Pathogenic
FATHMM_MKL
Uncertain
D
Vest4
GERP RS
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at